2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1874

Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Abstract Number: 1875

Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
Abstract Number: 1876

Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids
Abstract Number: 1877

Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
Abstract Number: 1878

Quantifying the Placebo Effect After Intra-Articular Injections: Implications for Trials and Practice
Abstract Number: 1879

The Relation of Pain Sensitization and Conditioned Pain Modulation to Pain Patterns in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Abstract Number: 1880

Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
Abstract Number: 1881

Association of Pain Centralization with DMARD Response in Active RA
Abstract Number: 1882

Anti-CCP Antibody and Pain Sensitization in Rheumatoid Arthritis
Abstract Number: 1883

Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients
Abstract Number: 1884

Autoantibodies to Malondialdehyde-acetaldehyde Preceding the Diagnosis of Rheumatoid Arthritis
Abstract Number: 1885

A Search to the Target Tissue in Which RA-specific Inflammation Starts: A Detailed MRI Study to Improve Identification of RA-specific Features in the Phase of Clinically Suspect Arthralgia
Abstract Number: 1886

Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors
Abstract Number: 1887

Anti-Mitochondrial Antibodies Predict Severe Erosive Disease in Rheumatoid Arthritis
Abstract Number: 1888

Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].